Visit Greenlight Guru's Virtual Booth

Learn more about us and chat with our team

Understanding Post-market Surveillance under EU MDR: Being Proactive, not Reactive

A session by Carolyn Guthrie
Director of QA / RA, Kapstone Medical

Register to watch this content

By submitting your email you agree to the terms
Watch this content now

About this talk

While the enforcement of EU MDR might have been delayed another year, your preparations addressing requirements for post-market surveillance (PMS) should not be! These new PMS requirements push manufacturers to take a more active role in monitoring of their devices to ensure that the benefit-risk profile of the device remains current. Performing PMS activities, according to the risk class of the device, requires a cross-functional team to ensure the required sources of data can be accessed and accurate data gathered. In this session, learn why it is important that PMS is not a one-size fits all approach, with considerations for risk of device, lifetime of device, time of the market, and more.

Talk takeaways: • Understanding the new requirements of PMS under MDR • What is the impact to the business? • How do the requirements affect your current product lifecycle approach/QMS? • Relationship between PMCF and PMS • What to include in your plans and reports?


Kapstone Medical, founded in 2007, is a single-source service provider to medical device companies lacking the appropriate human capital to commercialize new and safe products. We offer customized solutions that are flexible and cost-effective in an ever-changing regulatory environment. Our services span five main areas: product development, quality assurance, regulatory affairs, intellectual property strategy, and manufacturing solutions.

Carolyn Guthrie

Regulatory Affairs Certificate (RAC) US

Brought to you by